latest update:
[TrialBase DB]

trial summary · NCT07388524

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Lung Non-Small Cell Carcinoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07388524phase PHASE3enrollment 336start 2027-03-02

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

Source record: https://clinicaltrials.gov/study/NCT07388524

Facts

registry idNCT07388524
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionLung Non-Small Cell Carcinoma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment336
start date2027-03-02
primary completion2032-09-30
completion2032-09-30
results postednot reported

Conditions

  • Lung Non-Small Cell Carcinoma

Interventions

  • Atezolizumab
  • Atezolizumab and Recombinant Human Hyaluronidase
  • Biospecimen Collection
  • Computed Tomography
  • Patient Observation

Countries

  • United States

Intervention types: BIOLOGICAL, OTHER, PROCEDURE

Work with this record